Background:

Pre-existing cardiovascular diseases (CVD) conditions have prognostic implications in COVID-19. This study assesses the outcomes of COVID-19 infection among CVD hospitalized patients.

Methods:

We queried a multicentric, National COVID Cohort Collaboration (N3C) registry from March 2020-September 2021 to extract the cases of COVID-19 positive tests. COVID-19 RT-PCR tests done 21 days before or 5 days after the index hospitalization was considered. Patients with chronic heart failure, ischemic or valvular heart disease, peripheral vascular disease, prior cardiac surgery, or the presence of cardiovascular implantable electronic devices before the index admissions were included in CVD group. We reported crude and adjusted odd ratio (aOR), and 95% confidence intervals. Charlson comorbidity index and patient demographics were used for the adjustments.

Results:

Our study included 601,074 patients; among them 14% had preexisting CVD. The cohort includes 52.5% female, 16% Hispanic/Latino, 20% Black. Patients with CVD disease had a higher odd of mortality (aOR: 1.16[1.12-1.19];p<0.001) than patients without CVD. Similarly, patients with CVD had a higher odds of MACE (aOR: 2.17[2.12,2.32];p<0.001) than the non-CVD group. The incidence of ECMO and MV utilization and need for ICU admission were also significantly higher in the CVD group (Table 1). Table 1: Odd ratios

Conclusion:

The presence of CVD conditions is associated with higher morbidity and mortality among COVID-19 positive cases.

Footnotes